FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C. 20549
-------------	------------

Check this box if no longer subject
to Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b).
obligations may continue. See

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL								
OMB Number: 3235-0287								
Estimated average burden								
hours per response:	0.5							

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Ho Carole						2. Issuer Name and Ticker or Trading Symbol Denali Therapeutics Inc. [DNLI]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner						
(Last) C/O DEN	3. Date of Earliest Transaction (Month/Day/Year) 02/08/2023										X Officer (give title Other (specify below) Chief Medical Officer									
(Street) SOUTH FRANCI	SCO CA		4080		4. If	f Amendment, Date of Original Filed (Month/Day/Year)								Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person						
(City)	(518		<u>Z</u> ip)	lon-Deriva	tivo	Sacur	ritios	· Ac	auire	d Di	isnosad o	f or F	Ronofi	cial	ly Own					
Table I - Non-Deriva 1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Yd			n 2A. Deemed Execution Date		3. Transactio		action	4. Securities	Acquired (A) or (D) (Instr. 3, 4 a			5. Amount of Securities Beneficially Owned Followin		Form	nership : Direct Indirect str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)				
									Code	v	Amount	(A) or (D)	Price		Reported Transaction(s) (Instr. 3 and 4)				(111501.4)	
Common Stock				02/08/20	123				S ⁽¹⁾		1,521	D	\$30.8	88(2)	²⁾ 180,183 ⁽³⁾				See footnote ⁽⁴⁾	
Common Stock														25	,000	I		See footnote ⁽⁵⁾		
Common Stock												127,217(3)(6)		D						
		Tal	ole II								posed of, convertib				Owne	d				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	Exed) if an	Deemed cution Date,	4. Trans	action (Instr.	5. Numbe of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exe Expiration (Month/Day		rcisable and Date	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. D S. (I	Price of erivative ecurity nstr. 5)	9. Number derivative Securitie Beneficia Owned Following Reported Transacti (Instr. 4)	re Owner Form: Direct or Indi		Beneficial Ownership t (Instr. 4)	
					Code	v	(A)	(D)	Date Exer	cisable	Expiration Date	Title	Amour or Number of Shares	ər						
•	n of Respons					-			*		-						,		-	
	-	tax obligations by the column 4 of Table I	•	•											on request	by the Cor	nmiccio	n staff the	Issuer or a	
security hold	er of the Issuer	, the Reporting Perso	n will	provide full in	formati	on regar	ding th	e nur	nber of s	shares s	sold at each sep	arate pri	ice.			by the Col	111115510	n starr, the	issuel, or a	
		hares to the Rohatgi-		-						_			y the Rep	porting	g Person.					
		ord by the Rohatgi-F		-				-	_											
		ord by the Rohatgi-F	io irre	vocable GSTT	rust for	r the ben	ent of	the R	eporting	g Person	n's children.									
	26,807 RSUs.																			
Remarks	••										/s/ ⁻	Tvler N	Vielsen	ı. bv	power o	of				

<u>attorney</u>

** Signature of Reporting Person

02/10/2023

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.